跳至主要内容
临床试验/EUCTR2005-001578-28-EE
EUCTR2005-001578-28-EE进行中(未招募)不适用

Comparison the effects of Nebivolol versus Metoprolol succinate on endothelial function and large artery stiffness.A parallel group, randomized, double-blind, active control phase IV clinical trialNEMENDAS - NEMENDAS

Berlin-Chemie AG Menarini Group0 个研究点目标入组 80 人开始时间: 2005年11月11日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Patients with mild to moderate essential hypertension (systolic BP 140-179 mmHg and/or diastolic BP 90-109 mmHg)*
  • -Male and female patients aged 30-65 years
  • * Newly diagnosed untreated patients or previously diagnosed patients who were without treatment at least two weeks prior to screening* If patient has been taken previously antihypertensive medication the BP values are originated after untreated two weeks before randomization
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Concomitant medication: Cyclic antidepressants, MAO inhibitors, corticosteroids
  • -Diabetes I or II typus (fasting venous plasma glucose > 6.4 mmol/l)
  • -Bronchial asthma and chronic obstructive airway disease
  • -Body mass index > 30 kg/m2
  • -Ischaemic heart disease (III, IV stage, Canadian Cardiovascular Society)
  • -Clinically relevant heart failure (NYHA class II - IV
  • -Clinically relevant valve disease (physical examination)
  • -Arrhytmias and conduction disturbances, requiring therapy, sinus bradycardia at rest < 50 b/min, sick sinus syndrome, AV - block stage II – III
  • -Secondary hypertension (urea >8.3 mmol/l, creatinine >120µmol/l (males), >103 µmol/l (females), TSH > 4.0mIU/l, free T4 > 27 pmol/l)
  • -Clinically relevant atherosclerotic disease of lower extremities
  • -Acute inflammation (according to CRP > 10mg/l)
  • -Hypercholesterolemia (> 6,5 mmol/l)
  • -Allergic reaction to ?-blockers
  • -Pregnant or breast-feeding women
  • -History of hepatic, renal, metabolic or endocrine diseases
  • -Smoking > 10 cigarettes per day
  • -Alcohol consumption > 7 drinks per week (drink = 0,33 l beer, 120 ml wine or 30 ml strong alcoholic drink)
  • -The patient has had surgery or disease of the gastrointestinal tract which, in the opinion of the investigator, may influence the absorption or elimination of the study drug
  • -The patient has a severe organic disorder that may interfere with the absorption, pharmacokinetics, or elimination of the study medication.
  • -The patient has a comorbid condition that would be expected to result in death during the trial period (e.g., terminal cancer, AIDS)
  • -The patient has chronic psychoses or behavioural conditions that would limit the ability of the patient to comply with the requirements of this study
  • -The patient has known hypersensitivity to Nebivolol, Metoprolol or hydrochlorothiazide related compounds
  • -Patient is enrolled in another clinical trial.

研究者

发起方
Berlin-Chemie AG Menarini Group

相似试验

Comparison the effects of Nebivolol versus... | 临床试验